Radium

Summary

Radium (CHEMBL4300465) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 6
• Chemistry: 226.02541 Da · Ra

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4300465
Name	Radium
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6328144
ChEBI	CHEBI:33325
Molecular formula	Ra
Molecular weight	226.02541
InChIKey	HCWPIIXVSYCSAN-UHFFFAOYSA-N

SMILES: [Ra]

IUPAC name: radium

Parent form; salt/anhydrous children: CHEMBL4297420

Patent coverage: 1,158 distinct patent families (2,580 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,578 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02390934	PHASE2	COMPLETED	Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
NCT02656563	PHASE2	WITHDRAWN	Radium 223 Following Intermittent ADT
NCT02396368	PHASE1	WITHDRAWN	A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
NCT03737370	PHASE1	COMPLETED	Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT02925702	Not specified	UNKNOWN	PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.
NCT04587427	Not specified	COMPLETED	A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).